Novaquest Capital Management
NovaQuest Capital Management is a Raleigh-based life science investment firm that provides non-dilutive PRODUCT FINANCE™ capital to late-stage biopharmaceutical and animal health companies. Founded in 2010 as a spin-out from Quintiles/IQVIA, it manages over $2.5 billion across four funds and has executed more than 35 structured royalty and equity investments.
- Company typePrivate
- Founded2010
- HeadquartersRaleigh, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Novaquest Capital Management does
NovaQuest Capital Management, L.L.C. is a privately held life science investment manager founded in 2010 and headquartered in Raleigh, North Carolina. The firm was formed as a spin-out from Quintiles Transnational (now IQVIA), where the founding team had operated a strategic investment arm since 2000, and it has since raised more than $2.5 billion across four institutional funds: Product Finance Fund III (~$500M, 2015), Fund IV (~$900M, 2019), and Fund V (~$1.2B) plus Private Equity Fund I (~$275M), both in 2020.
The firm's core product is PRODUCT FINANCE™, a trademarked structured finance methodology that provides non-dilutive capital to late-stage biopharmaceutical and animal health companies through royalty, milestone, and revenue-interest agreements. Typical deal structures include an upfront capital payment in exchange for quarterly mid-single-digit royalties on worldwide net sales, capped total payments, and contingent milestones tied to regulatory approvals. Disclosed transactions range from $3.6 million venture rounds to an up-to-$260 million revenue interest financing with Phathom Pharmaceuticals, and span therapeutic areas including oncology, immunology, regenerative medicine, gastrointestinal, rare disease, women's health, veterinary diagnostics, animal stem cell therapy, and poultry health.
NovaQuest makes money through three primary streams: management fees on committed and invested fund capital, royalty and milestone payments from portfolio companies on approved products, and capital appreciation from equity co-investments and successful exits (for example, the AbbVie acquisition of Cerevel Therapeutics in 2024). The firm serves two horizontal segments — biopharmaceutical companies with promising late-stage clinical assets and animal health companies needing development capital — and distributes its capital via direct enterprise outreach, an explicit intermediary program ([email protected]), Product Finance Investment Roundtables, and an 11–50 person team that includes former pharmaceutical operators from Eli Lilly, Merck KGaA, and IQVIA.
Novaquest Capital Management firmographics
Firmographics- Name
- Novaquest Capital Management
- Legal name
- NovaQuest Capital Management, L.L.C.
- Website
- https://novaquest.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NovaQuest Capital Management is a Raleigh-based life science investment firm that provides non-dilutive PRODUCT FINANCE™ capital to late-stage biopharmaceutical and animal health companies. Founded in 2010 as a spin-out from Quintiles/IQVIA, it manages over $2.5 billion across four funds and has executed more than 35 structured royalty and equity investments.
- Ownership category
- akta.pro rank
Where Novaquest Capital Management is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Novaquest Capital Management business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Royalty Payments: NovaQuest earns royalty payments on future worldwide annual net sales of approved products. Payments are typically structured as quarterly mid single-digit royalty payments on approved products, with caps on total payments.
- Milestone Payments: Portfolio companies make milestone payments upon regulatory approvals (e.g., FDA approval of products). These are contingent payments tied to development and commercialization milestones.
- Investment Returns: Capital appreciation through equity investments and revenue interest financing arrangements in portfolio companies, including successful exits through acquisitions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom structured financing for late-stage biopharma investments |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Novaquest Capital Management product offering
Product offeringCore offering
NovaQuest provides non-dilutive structured finance investments (PRODUCT FINANCE™) to late-stage biopharmaceutical companies in exchange for royalty and milestone payments on approved products. It also deploys capital into an Animal Health Strategy supporting veterinary therapeutics, diagnostics, and vaccine developers, plus a Private Equity Fund and Healthcare Technology and Services partnerships. Across four funds the firm has raised more than $2.5 billion and executed 35+ portfolio investments since 2010.
Product overview
NovaQuest Capital Management is a life science investment firm offering two core investment products: PRODUCT FINANCE™ for late-stage biopharmaceutical development and an Animal Health Strategy for animal health companies. PRODUCT FINANCE™ provides non-dilutive capital through royalty and revenue interest structures to fund pivotal clinical trials and commercialization. The Animal Health Strategy supports development of animal health products and technologies. NovaQuest has deployed over $2.5 billion across more than 35 investments through these strategies, which are complemented by healthcare technology and services partnerships.
Differentiator
Problem solved
Functional benefit
Products and services
- PRODUCT FINANCE™ NovaQuest's signature structured finance product providing non-dilutive capital to late-stage biopharmaceutical companies in exchange for royalty payments on future worldwide net sales of approved products and milestone payments tied to regulatory approvals. Used to fund pivotal clinical trials, regulatory submissions, and commercial launches without diluting founder or shareholder equity.
- Animal Health Strategy Investment strategy focused on partnerships with animal health companies, providing equity, debt, and structured capital to support development and commercialization of veterinary therapeutics, diagnostics, and vaccine technologies. Includes direct investments, Series A/B/C participation, and royalty or revenue interest structures.
- Private Equity Fund Private equity fund providing growth and expansion capital to healthcare and life science companies, complementing the firm's core product finance and animal health strategies with broader company-level investments.
- Healthcare Technology and Services Partnerships Partnerships with healthcare technology and services companies that complement NovaQuest's core biopharma and animal health investment strategies, including investments in clinical research organizations, pharma services, and healthcare technology providers.
Quantifiable outcome
- First FDA-approved medication for RVVC (VIVJOA)
- +1 more outcomes
Companies that use Novaquest Capital Management
Customer profileNamed customers10 records
Segments2 records
Ideal customer profiles3 records
Novaquest Capital Management technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Novaquest Capital Management partnerships and signals
Strategic signalScale indicators8 records
Recent moves8 records
Expansion highlights6 records
Novaquest Capital Management competitors and assessment
Company assessmentBroad incumbents
- Perceptive Advisors:
- Deerfield Management: Deerfield Management is a large healthcare-focused investment firm offering structured debt, equity, and royalty financing across biopharma and medical devices. With significantly larger AUM and a broader product set, Deerfield competes with NovaQuest for late-stage biopharma structured financing opportunities and is a comparable sector specialist.
- Royalty Pharma: Royalty Pharma is the largest biopharmaceutical royalty buyer globally, purchasing both development-stage and commercial royalties from biopharma companies. While its scale, public-market presence, and preference for commercial-stage royalties differ from NovaQuest's late-stage product finance focus, it directly competes for the highest-quality biopharma royalty and revenue interest transactions.
Direct peers
- HealthCare Royalty Partners: HealthCare Royalty Partners (HCR) is one of the largest dedicated healthcare royalty and structured finance firms, deploying capital into biopharma late-stage assets via similar royalty, revenue interest, and synthetic royalty structures as NovaQuest's PRODUCT FINANCE™. Both target non-dilutive capital for pivotal trials and commercial launches, making HCR the closest direct competitor.
- Innovatus Capital Partners: Innovatus Capital Partners manages life sciences and structured finance strategies that provide non-dilutive capital to biopharma companies through royalty, revenue interest, and specialty debt structures. Its product-finance-style offerings to mid- and late-stage biopharma directly overlap with NovaQuest's PRODUCT FINANCE™ strategy.
- OrbiMed: OrbiMed is a sector-focused healthcare investment firm spanning venture, growth, royalty, and credit strategies across biopharma and medical devices. Like NovaQuest, OrbiMed deploys structured capital into healthcare with specialist underwriting teams, and competes with NovaQuest for late-stage biopharma financings and broader healthcare venture opportunities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Novaquest Capital Management social profiles
Digital presenceNovaquest Capital Management financial estimates
Financial estimateRevenue estimate
Valuation estimate
Novaquest Capital Management leadership team
Management profileNumber of profiles
Profiles20 records
Novaquest Capital Management funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Novaquest Capital Management M&A and investment
M&A and investmentM&A8 records
Investments36 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Novaquest Capital Management
What does Novaquest Capital Management do?
NovaQuest provides non-dilutive structured finance investments (PRODUCT FINANCE™) to late-stage biopharmaceutical companies in exchange for royalty and milestone payments on approved products. It also deploys capital into an Animal Health Strategy supporting veterinary therapeutics, diagnostics, and vaccine developers, plus a Private Equity Fund and Healthcare Technology and Services partnerships. Across four funds the firm has raised more than $2.5 billion and executed 35+ portfolio investments since 2010.
Is Novaquest Capital Management a public or private company?
Novaquest Capital Management is a private company. It is classified as management employee owned and is currently operating.
When was Novaquest Capital Management founded?
Novaquest Capital Management was founded in 2010. It employs 11 to 50 people.
Where is Novaquest Capital Management based?
Novaquest Capital Management is headquartered in Raleigh, United States, in the North America region.
How does Novaquest Capital Management make money?
Three revenue lines are on record. Royalty Payments are the primary driver. The others are milestone Payments and investment Returns.
Who are Novaquest Capital Management's main competitors?
Broad incumbents on record are Perceptive Advisors, Deerfield Management and Royalty Pharma. Direct peers are HealthCare Royalty Partners, Innovatus Capital Partners and OrbiMed.
Does Novaquest Capital Management have an API?
No public API is recorded for Novaquest Capital Management.